89bio CMO touts advantages of pegozafermin following Phase III initiation

89bio recently revealed the initiation of the Phase III ENLIGHTEN-Cirrhosis trial of its flagship FGF21 analog, pegozafermin, in patients with metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis. The announcement followed the November release of strong results for pegozafermin in F4 patients, albeit with a very small sample size. Clinical Trials Arena spoke to 89bio’s chief medical officer Hank Mansbach about the news, discussing potential strengths that the asset could have over its competitors.